Ivosidenib Drugs Market Size, Share, Growth, and Industry Analysis, By Type (60 Tablets, 30 Tablets), By Application (Hospital, Pharmacy) and Regional Forecast to 2033

Updated On : 24 July, 2025

IVOSIDENIB DRUGS MARKET REPORT OVERVIEW

The global Ivosidenib Drugs Market is poised for significant growth, starting at USD 0.18 billion in 2024, rising to USD 0.19 billion in 2025, and projected to reach USD 0.28 billion by 2033, with a CAGR of 4.8% from 2025 to 2033.

Ivosidenib, a targeted therapy, has gained prominence in the pharmaceutical market for its role in treating certain cancers. Specifically designed to inhibit mutated isocitrate dehydrogenase 1 (IDH1) enzymes, Ivosidenib is primarily used in the management of acute myeloid leukemia (AML) and cholangiocarcinoma. By targeting the genetic mutations associated with these malignancies, Ivosidenib aims to disrupt the abnormal cellular processes, offering a novel approach to cancer treatment. As ongoing research explores its efficacy in other indications, Ivosidenib continues to represent a promising advancement in precision medicine, providing hope for patients with specific genetic alterations driving their diseases.

Key Findings

• Market Size and Growth: The global market is expected to grow from USD 0.19 billion in 2025 to USD 0.28 billion by 2033, registering a CAGR of 4.8%.

• Key Market Trends: Over 35% of ongoing clinical research is focused on expanding Ivosidenib's use beyond AML and cholangiocarcinoma to other IDH1-mutated cancers.

• Key Market Drivers: A growing genomic understanding has led to a 40% increase in precision therapy approvals, driving Ivosidenib’s adoption.

• Technological Advancements: Biomarker identification tools used in Ivosidenib prescription have increased by 28% since 2021, supporting targeted treatment decisions.

• Regional Growth: North America holds the largest share at 41%, followed by Europe (28%), Asia Pacific (21%), and the rest of the world (10%).

• Type Segmentation: 60-tablet packs dominate with 64% market share due to longer treatment cycles; 30-tablet packs account for the remaining 36%.

• Application Segmentation: Hospitals account for 58% of usage due to complex patient monitoring, while pharmacies support 42% through outpatient access.

• Key Players: Servier Pharmaceuticals leads the market with an estimated 72% share in 2025, given its exclusive rights to Ivosidenib development and distribution.

COVID-19 Impact on the Market Growth Restrained by Pandemic due to Travel Restrictions

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic has significantly impacted the Ivosidenib drugs market, causing disruptions in manufacturing, supply chains, and healthcare delivery. Lockdowns, travel restrictions, and resource reallocation to combat the pandemic have led to delays in clinical trials, hindering drug development timelines. Furthermore, the diversion of healthcare resources towards managing COVID-19 has affected routine medical care, impacting patient diagnoses and treatment initiation. Economic uncertainties and reduced healthcare budgets also pose challenges for Ivosidenib market growth. Despite its potential benefits, the pandemic-induced obstacles have slowed down the progress of Ivosidenib adoption and market expansion, highlighting the broader challenges faced by the pharmaceutical industry during global health crises.

LATEST TRENDS

"Leveraging Edge Computing Integration in Ivosidenib Drugs to Propel Market Growth"

The latest trend in the Ivosidenib drugs market involves ongoing research and development efforts to expand its therapeutic applications. While initially recognized for treating acute myeloid leukemia (AML) and cholangiocarcinoma, recent studies explore Ivosidenib's potential in addressing other cancers with relevant genetic mutations. Additionally, advancements in precision medicine and biomarker identification contribute to personalized treatment approaches. The market is witnessing increased collaborations between pharmaceutical companies and research institutions to unlock Ivosidenib's full potential across a spectrum of malignancies, emphasizing the evolving landscape of targeted therapies and the continuous pursuit of innovative solutions in cancer treatment.

IVOSIDENIB DRUGS MARKET SEGMENTATION

By Type

Based on type the market can be categorized into 60 Tablets, 30 Tablets.

• 60 Tablets: Ivosidenib, a targeted therapy for certain cancers, is typically available in tablet form. The market offers Ivosidenib in 60-tablet packs. These tablets contain the active ingredient that inhibits specific mutations, providing a tailored treatment approach. The 60-tablet presentation aligns with prescribed regimens, facilitating patient adherence and effective management of the targeted therapy.
• 30 Tablets: Ivosidenib, a targeted therapy for specific cancers, is also available in a 30-tablet presentation. This option provides flexibility in dosage and treatment duration, accommodating individual patient needs and prescribed regimens. The 30-tablet pack ensures a convenient and manageable supply for patients undergoing Ivosidenib therapy.

By Application

Based on application the market can be categorized into Hospital, Pharmacy.

• Hospital: In the Ivosidenib drugs market, the application category prominently includes hospital usage. Hospitals serve as primary settings for administering this targeted therapy, ensuring close medical supervision and comprehensive care. Ivosidenib's application in hospitals underscores its role in structured healthcare environments for effective management of specific cancer types.
• Pharmacy: The Ivosidenib drugs market extends its application into pharmacies, enabling accessibility and distribution beyond hospital settings. Pharmacies play a crucial role in facilitating patient access to Ivosidenib, ensuring a seamless supply chain and convenient availability for individuals prescribed this targeted therapy for certain cancers.

DRIVING FACTORS

"Growing Understanding of Genetic Mutations to Propel the Market Growth"

Advancements in genomic research and a deeper understanding of genetic mutations associated with various cancers are a primary driving factor in the Ivosidenib drugs market growth. As precision medicine gains prominence, the identification of patients with specific genetic alterations, such as isocitrate dehydrogenase 1 (IDH1) mutations, becomes crucial. Ivosidenib's targeted approach, inhibiting mutated IDH1 enzymes, aligns with this trend, making it a promising therapeutic option. The increasing knowledge about the molecular basis of cancers and the role of Ivosidenib in addressing these mutations propels its adoption, fostering a paradigm shift towards more precise and effective treatments.

"Rising Focus on Personalized Cancer Therapies to Drive the Market Growth"

The Ivosidenib drugs market is also driven by the broader trend towards personalized cancer therapies. With an increasing emphasis on tailoring treatments based on individual patient characteristics, Ivosidenib exemplifies a targeted and personalized approach. The drug's ability to specifically target mutated IDH1 enzymes, which drive certain cancers, aligns with the personalized medicine paradigm. As healthcare shifts towards treatments tailored to patients' unique genetic profiles, Ivosidenib's role in offering a customized solution underscores its significance in the evolving landscape of cancer therapeutics, contributing to the momentum of personalized medicine in oncology.

RESTRAINING FACTOR

"High Cost Pose Potential Impediments to the Market Growth"

A notable restraint in the Ivosidenib drugs market is the high cost associated with precision medicine and targeted therapies. The intricate research, development, and production processes for drugs like Ivosidenib contribute to elevated pricing. Additionally, the need for advanced diagnostic tests to identify specific genetic mutations adds to the overall treatment expenses. This high financial burden may limit accessibility for some patients and strain healthcare budgets. Economic considerations, coupled with reimbursement challenges, pose obstacles to widespread adoption. Overcoming these cost-related barriers requires strategic efforts to enhance affordability and ensure broader patient access to Ivosidenib, addressing a critical aspect of market sustainability and inclusivity.

IVOSIDENIB DRUGS MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

"North America to Dominate the Market due to Robust Healthcare Infrastructure"

North America is poised to play a leading role in the Ivosidenib drugs market share. The region's dominance is attributed to its robust healthcare infrastructure, advanced research capabilities, and a strong focus on precision medicine. The United States, in particular, boasts a well-established pharmaceutical industry, facilitating efficient drug development and commercialization. Additionally, the region's regulatory environment supports the approval and adoption of innovative therapies like Ivosidenib. Collaborations between academic institutions, pharmaceutical companies, and research centers further contribute to advancements in the field. With a favorable ecosystem for cutting-edge medical interventions, North America stands as a key driver in shaping the trajectory of the Ivosidenib drugs market.

KEY INDUSTRY PLAYERS

"Key Players Transforming the Ivosidenib Drugs Landscape through Innovation and Global Strategy"

Key players in the Ivosidenib drugs market, including pharmaceutical companies and research institutions, play a pivotal role in drug development, clinical trials, and market expansion. Their expertise in precision medicine, strategic collaborations, and commitment to advancing cancer therapeutics contribute significantly to shaping the landscape and ensuring the drug's effective integration into clinical practice.

List of Market Players Profiled

• Servier Pharmaceuticals (France)

INDUSTRIAL DEVELOPMENT

May,2021: Servier Pharmaceuticals announced the FDA approval of TIBSOVO (ivosidenib) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory myelodysplastic syndromes (MDS). This is the first and only approved targeted therapy for this molecularly defined subset of R/R MDS patients, further solidifying Servier's leadership in mutant IDH inhibition.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.